Cargando…
Novel Immunotherapeutic Strategies of Gastric Cancer Treatment
Gastric cancer (GC) is the fourth most common cancer and the second most frequent cause of cancer-related deaths, accounting for 10.4% of cancer deaths worldwide. Despite the improvements, estimated cure rates for patients with advanced stages remain poor, and in the metastatic setting, chemotherapy...
Autores principales: | Amedei, Amedeo, Benagiano, Marisa, della Bella, Chiara, Niccolai, Elena, D'Elios, Mario M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255571/ https://www.ncbi.nlm.nih.gov/pubmed/22253528 http://dx.doi.org/10.1155/2011/437348 |
Ejemplares similares
-
Skin CD30(+) T cells and circulating levels of soluble CD30 are increased in patients with graft versus host disease
por: Amedei, Amedeo, et al.
Publicado: (2013) -
T Cells in Gastric Cancer: Friends or Foes
por: Amedei, Amedeo, et al.
Publicado: (2012) -
T Cells and Adoptive Immunotherapy: Recent Developments and Future Prospects in Gastrointestinal Oncology
por: Amedei, Amedeo, et al.
Publicado: (2011) -
What Is Recent in Pancreatic Cancer Immunotherapy?
por: Niccolai, Elena, et al.
Publicado: (2013) -
Increased IL-17A Serum Levels and Gastric Th17 Cells in Helicobacter pylori-Infected Patients with Gastric Premalignant Lesions
por: Della Bella, Chiara, et al.
Publicado: (2023)